铑(II)可以通过分子内的氮杂C–H插入反应有效地促进芳基氨基甲酸酯底物的活化和环化,从而生成苯并恶唑啉酮。对底物范围的研究表明,该反应在更不稳定的o -C(sp 3)-H键上进行了选择性芳族C(sp 2)-H胺化反应。反向二次KIE的观察结果(P H / P D = 0.42±0.03)表明,芳族亲电取代机理参与了芳基CH酰胺化反应。
[EN] OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS<br/>[FR] COMPOSÉS OXAZOLIDINONE ET PROCÉDÉS D'UTILISATION DE CES DERNIERS EN TANT QU'AGENTS ANTIBACTÉRIENS
申请人:MERCK SHARP & DOHME
公开号:WO2017066964A1
公开(公告)日:2017-04-27
The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosiscomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or apharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
[EN] OXAZOLIDINONE HYDROXAMIC ACID COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS D'ACIDE OXAZOLIDINONE-HYDROXAMIQUE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
申请人:NOVARTIS AG
公开号:WO2015066413A1
公开(公告)日:2015-05-07
This invention pertains generally to treating bacterial infections using organic compounds of Formula I. In certain aspects, the invention pertains to treating infections caused by Gram-negative bacteria. (I) wherein X, Y, R1, R2, R3, R4 and R5 and defined herein.
[EN] HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET LEURS APPLICATIONS PHARMACEUTIQUES
申请人:SUNSHINE LAKE PHARMA CO LTD
公开号:WO2016000615A1
公开(公告)日:2016-01-07
The present invention provides herein is a heteroaryl compound or a stereoisomer, a geometric isomer, a tautomer, a racemate, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, as well as a pharmaceutical composition containing the compound disclosed herein. The present invention also provides herein is use of the compound or the pharmaceutical composition thereof disclosed herein in the manufacture of a medicine for treating autoimmune diseases or proliferative diseases.
A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.
Superparamagnetic Fe<sub>3</sub>
O<sub>4</sub>
Nanoparticles in a Deep Eutectic Solvent: An Efficient and Recyclable Catalytic System for the Synthesis of Primary Carbamates and Monosubstituted Ureas
Superparamagnetic Fe3O4 nanoparticles were used to prepare primary carbamates as well as monosubstituted and N,N‐disubstituted ureas. This efficient phosgene‐free process used urea as an eco‐friendly carbonyl source in the presence of a biocompatible deep eutectic solvent (DES) to provide an inexpensive and attractive route that afforded the products in moderate to excellent yields. (MNP = magnetite nanoparticles
超顺磁性Fe 3 O 4纳米颗粒用于制备氨基甲酸酯以及单取代的和N,N-二取代的脲。这种有效的无光气工艺在生物相容性深共熔溶剂(DES)的存在下将尿素用作环保的羰基来源,从而提供了一种廉价且有吸引力的途径,使产品收率适中至优异。(MNP =磁铁矿纳米颗粒,Ch =胆碱)